Injectables
Allergan Aesthetics Wins Health Canada Approval for Boey — Rapid-Onset Neuromodulator Enters North American Market
New rapid-onset, short-duration toxin approved in Canada; U.S. pathway unclear.
Photo: Laura Beauty Designer | Brasil / Pexels
AI Inside MedSpa Intelligence · Jun 26, 2026
Allergan Aesthetics has received Health Canada approval for Boey, a rapid-onset and short-duration neuromodulator indicated for glabellar lines. Boey represents a new category within the neuromodulator space, designed to work faster and wear off sooner than traditional Botox and Dysport formulations.
The approval in Canada signals Allergan's continued innovation in the toxin market and potential future expansion into the U.S. market. For North American medspa owners, Boey's rapid onset and shorter duration could appeal to patients seeking flexibility or those new to neuromodulation. The competitive landscape for botulinum toxin products continues to evolve, with multiple duration profiles now available or in development.
Boey approved in Canada as a rapid-onset, short-duration neuromodulator for glabellar lines.
Source: original report ↗
Frequently asked questions
What is Boey and how is it different from Botox?
Boey is a rapid-onset, short-duration neuromodulator approved by Health Canada for glabellar lines. Unlike traditional Botox and Dysport, Boey works faster and wears off sooner, offering patients more flexibility and a shorter commitment to results.
Is Boey available in the United States?
Boey has received Health Canada approval but is not yet approved in the U.S. The U.S. regulatory pathway remains unclear, so availability in American medspa clinics is not yet determined.
What patient types would benefit most from Boey?
Boey appeals to patients seeking flexibility in treatment timing and those new to neuromodulation who want to test results before committing to longer-lasting products. The shorter duration makes it ideal for patients who want reversibility or prefer more frequent touch-ups.
How does the rapid-onset profile of Boey impact treatment scheduling?
Boey's rapid onset means patients see results faster than with traditional Botox or Dysport, reducing the typical 3-7 day wait for full effects. This could allow clinics to schedule follow-up consultations sooner and improve patient satisfaction with treatment timelines.
What does Boey's approval signal for the neuromodulator market?
Boey's approval demonstrates continued innovation in the toxin space, with manufacturers now developing products with varied duration profiles. This expands the competitive landscape and gives medspa owners more options to differentiate their services and meet diverse patient preferences.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
